Actively Recruiting

Age: 30Years - 34Years
All Genders
Healthy Volunteers
ID06275204

Multicentric Transnational H. Pylori Screen-and-treat Study in a Population of Young Adults

Led by University of Latvia · Updated on 2024-03-05

6800

Participants Needed

7

Research Sites

8 weeks

Total Duration

On this page

Sponsors

U

University of Latvia

Lead Sponsor

C

Clinical Hospital Center Rijeka

Collaborating Sponsor

AI-Summary

What this Trial Is About

Gastric cancer is a significant public health challenge globally, with a major portion of cases in Europe linked to Helicobacter pylori infection. This research aims to evaluate a population-based H. pylori test-and-treat strategy to prevent gastric cancer in young adults aged 30 to 34 across several European countries. The study focuses on assessing the program's processes, feasibility, acceptance, and effectiveness in reducing infection and related cancer risks. Participants who test positive for H. pylori will receive treatment according to local protocols, including a 14-day course of either bismuth-based quadruple therapy or standard triple therapy. If the first treatment fails, a secondary treatment with levofloxacin-based therapy will be offered. The study is conducted in seven centers across Croatia, Ireland, Latvia, Poland, Romania, and Slovenia, each following specific testing and treatment procedures. During the study, participants will be interviewed about early childhood risk factors and habits such as alcohol and tobacco use. Researchers will monitor treatment adherence, infection eradication success, adverse effects, and reasons for dropping out. The study duration extends from 2024 to 2026, allowing for recruitment, treatment, retesting, and thorough data analysis to inform future gastric cancer prevention strategies in Europe.

CONDITIONS

Brief Title

H. Pylori Screen-and-treat Study in a Population of Young Adults

Who Can Participate

Age: 30Years - 34Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Young adults generally between 30 and 34 years of age
Not Eligible

You will not qualify if you...

  • Individuals with mental or developmental limitations who cannot give fully informed consent
  • People previously treated for H. pylori infection
  • History of partial or total stomach surgery due to benign or malignant conditions

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) for H. pylori testing and consent

Treatment

Duration - 14 consecutive days per treatment course

Participants who test positive for H. pylori will receive one of several antibiotic treatment regimens lasting 14 days, depending on the study center. Treatment includes bismuth-based quadruple therapy, standard triple therapy, or levofloxacin-based therapies.

1 to 2 visits depending on treatment response and center-specific protocol

Follow-up

Duration - Approximately 1 month post-treatment

Participants will be retested approximately one month after treatment completion to confirm eradication of H. pylori infection. Additional treatment may be offered if infection persists.

1 follow-up visit for eradication testing

Trial Site Locations

Total: 7 locations

1

University Hospital Centre Zagreb

Zagreb, City of Zagreb, Croatia, 10000

Actively Recruiting

2

Clinical Hospital Center Rijeka

Rijeka, Croatia, 51000

Actively Recruiting

3

Beacon Hospital

Dublin, Ireland, D18 AK68

Actively Recruiting

4

Clinical and Preventive Medicine of the University of Latvia

Riga, Latvia, LV1079

Not Yet Recruiting

5

Wroclaw Medical University

Wroclaw, Poland, 50-367

Actively Recruiting

6

Iuliu Hatieganu University of Medicine and Pharmacy

Cluj-Napoca, Cluj, Romania, 400003

Actively Recruiting

7

National Institute of Public Health, Slovenia

Ljubljana, Slovenia, 1000

Actively Recruiting

Loading map...

Research Team

P

Principal Investigator of the Study - Bojan Tepeš (National Institute of Public Health, Slovenia), Prof., MD

T

Tatjana Kofol Bric (National Institute of Public Health, Slovenia), MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

4

Similar Trials

Phase III Randomized Controlled Trial Comparing D2 Versus D3...

Gastric Cancer

Actively Recruiting

1 location

Clinical Outcomes of Indocyanine Green Tracer in 3D Plus Ult...

Gastric Cancer

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here